CCR4 and primary cutaneous T-cell non-Hodgkin lymphoma: Each compound exhibits unique characteristics, such as high affinity for CCR4, receptor internalisation capabilities, and potential synergies with anti-CPI drugs, laying the foundation for a more nuanced approach to CTCL treatment.